Advertisement
Cardon Children's Medical Center

Merck, Pfizer combo treatment boosts kidney cancer survival

Feb 12, 2019 , Reuters
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.


Read the full story...


Trending healthcare news keywords at this moment

digital medical drug doctors opioid study disease tied risk food blood media online gene therapy age higher linked outbreak kids states cdc fda sales women viewpoints social measles drugs people state highlights hospital americans care raise eating day cancer mental million raises year exercise finds children patients program babies series generic campaign walgreens adds ai target sleep heart brain -- tip fat price medicare bill cases report tobacco startup approves treat china make pressure device adhd cogentin